The effects of systemically administered methylprednisolone and recombinant human erythropoietin after acute spinal cord compressive injury in rats

Basit Öğe Kaydı
dc.contributor.authorCetin, Abdurrahman
dc.contributor.authorNas, Kemal
dc.contributor.authorBueyuekbayram, Hueseyin
dc.contributor.authorCeviz, Adnan
dc.contributor.authorOelmez, Goenuel
dc.date.accessioned2024-04-24T16:01:56Z
dc.date.available2024-04-24T16:01:56Z
dc.date.issued2006
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe study design was to decrease the damage of spinal cord on the experimentally induced acute spinal cord injury in rats. The objective of this study was to evaluate whether recombinant human erythropoietin (rHu-EPO) and methylprednisolone (MPSS) improve neurological function and histopathological changes if systemically administered after traumatic spinal cord injury. This study included 48 rats that underwent experimental SCI. Forty-eight animals were randomly divided into six groups. Animals constituted a moderate compression of 0.6 N that was produced by application of an aneurysm clip at level T3 for 1 min. rHu-EPO (1,000 and 3,000 U (Unit) per kg of body weight i.p.) and MPSS (30 mg/kg) were administered 5 min after injury, and control group was saline treated. (1) Control group (n=8), (2) MPSS group (n=8), (3) rHu-EPO 1,000 U group (n=8), (4) MPSS + rHu-EPO 1,000 U group (n=8), (5) rHu-EPO 3,000 U group (n=8), and (6) MPSS + rHu-EPO 3,000 U group (n=8). The neurological function and histopathology were evaluated at 24 and 72 h. According to the neurological functional test scores significant improvements between the control group and the other groups that had taken medical treatment were observed (P < 0.001). Histopathologically severe ischemic findings were observed in the control group. A significant decrease in ischemic damage was detected in MPSS + rHu-EPO 3,000 U group (P < 0.001). The most significant neurological functional and histopathological improvements were observed after systemical administration of MPSS + rHu-EPO 3,000 U and rHu-EPO 3,000 U. Furthermore, the MPSS + rHu-EPO 3,000 U group provides the most improved neurological functional and histopathological recovery.en_US
dc.identifier.doi10.1007/s00586-006-0091-2
dc.identifier.endpage1544en_US
dc.identifier.issn0940-6719
dc.identifier.issn1432-0932
dc.identifier.issue10en_US
dc.identifier.pmid16547753
dc.identifier.scopus2-s2.0-33750071388
dc.identifier.scopusqualityQ1
dc.identifier.startpage1539en_US
dc.identifier.urihttps://doi.org/10.1007/s00586-006-0091-2
dc.identifier.urihttps://hdl.handle.net/11468/14505
dc.identifier.volume15en_US
dc.identifier.wosWOS:000241355200014
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Spine Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSpinal Cord Injuryen_US
dc.subjectErythropoietinen_US
dc.subjectMethylprednisoloneen_US
dc.subjectNeurological Functionen_US
dc.subjectHistopathologyen_US
dc.titleThe effects of systemically administered methylprednisolone and recombinant human erythropoietin after acute spinal cord compressive injury in ratsen_US
dc.titleThe effects of systemically administered methylprednisolone and recombinant human erythropoietin after acute spinal cord compressive injury in rats
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu